Skip to main content
Top
Published in: Investigational New Drugs 1/2020

01-02-2020 | Glioblastoma | PRECLINICAL STUDIES

Discovery of a pyrimidine compound endowed with antitumor activity

Authors: Ludovica Taglieri, Francesco Saccoliti, Alice Nicolai, Giovanna Peruzzi, Valentina Noemi Madia, Valeria Tudino, Antonella Messore, Roberto Di Santo, Marco Artico, Samanta Taurone, Maurizio Salvati, Roberta Costi, Susanna Scarpa

Published in: Investigational New Drugs | Issue 1/2020

Login to get access

Summary

Recently, some synthetic nitrogen-based heterocyclic molecules, such as PJ34, have shown pronounced antitumor activity. Therefore, we designed and synthesized new derivatives characterized by a nitrogen-containing scaffold and evaluated their antiproliferative properties in tumor cells. We herein report the effects of three newly synthesized compounds on cell lines from three different human cancers: triple-negative breast cancer, colon carcinoma and glioblastoma. We found that two of these compounds did not affect proliferation, while the third significantly inhibited replication of the three cell lines. Moreover, this third molecule at 20 μM led to the upregulation of p21 and p27 and blockage of the cell cycle at G0/G1; in addition, it induced apoptosis in all three cell lines when used at higher concentrations (30–50 μM). The results demonstrate that this compound is a potent inhibitor of replication, an inducer of apoptosis and a negative regulator of cell cycle progression for cancer cells of different histotypes. Our data suggest a potential role for this new molecule as an interesting and powerful tool for new approaches in treating various cancers.
Literature
1.
go back to reference Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265CrossRef Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265CrossRef
2.
go back to reference Harrison MR, Holen KD, Liu G (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7:54–64PubMedPubMedCentral Harrison MR, Holen KD, Liu G (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7:54–64PubMedPubMedCentral
6.
go back to reference Castiel A, Visochek L, Mittelman L, Dantzer F, Izraeli S, Cohen-Armon M (2011) A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer 11:412–419CrossRef Castiel A, Visochek L, Mittelman L, Dantzer F, Izraeli S, Cohen-Armon M (2011) A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer 11:412–419CrossRef
10.
21.
go back to reference Li JH, Kalish VJ, Zhang J, Serdyuk LE, Ferraris DV, Xiao G, Kletzly PW (2001) Sulfonamide and carbamide derivatives of 6(5H) phenanthridinones and their uses. Patent WO2001090077A1. Li JH, Kalish VJ, Zhang J, Serdyuk LE, Ferraris DV, Xiao G, Kletzly PW (2001) Sulfonamide and carbamide derivatives of 6(5H) phenanthridinones and their uses. Patent WO2001090077A1.
22.
go back to reference Taglieri L, Nardo T, Vicinanza R, Ross JM, Scarpa S, Coppotelli G (2017) Thyroid hormone regulates fibronectin expression through the activation of hypoxia inducible factor 1. Biochem Biophys Res Commun 493:1304–1310CrossRef Taglieri L, Nardo T, Vicinanza R, Ross JM, Scarpa S, Coppotelli G (2017) Thyroid hormone regulates fibronectin expression through the activation of hypoxia inducible factor 1. Biochem Biophys Res Commun 493:1304–1310CrossRef
24.
go back to reference Georgakilas Ag MOA, Bonner WM (2017) P21: a two-faced genome guardian. Trends Mol Med 23:310–319CrossRef Georgakilas Ag MOA, Bonner WM (2017) P21: a two-faced genome guardian. Trends Mol Med 23:310–319CrossRef
25.
go back to reference Abbas T, Dutta A (2009) P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400–414CrossRef Abbas T, Dutta A (2009) P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400–414CrossRef
30.
go back to reference Yoon MK, Mitrea DM, Ou L, Kriwacki RW (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40:981–988CrossRef Yoon MK, Mitrea DM, Ou L, Kriwacki RW (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40:981–988CrossRef
Metadata
Title
Discovery of a pyrimidine compound endowed with antitumor activity
Authors
Ludovica Taglieri
Francesco Saccoliti
Alice Nicolai
Giovanna Peruzzi
Valentina Noemi Madia
Valeria Tudino
Antonella Messore
Roberto Di Santo
Marco Artico
Samanta Taurone
Maurizio Salvati
Roberta Costi
Susanna Scarpa
Publication date
01-02-2020
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-019-00762-y

Other articles of this Issue 1/2020

Investigational New Drugs 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine